Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients

  • Effi, Ahoua B (Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University) ;
  • Aman, N'guiessan A (Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University) ;
  • Koui, Baumaney S (Treichville Teaching Hospital) ;
  • Koffi, Kouadio D (Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University) ;
  • Traore, Zie C (Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University) ;
  • Kouyate, Mohamed (Treichville Teaching Hospital)
  • 발행 : 2016.06.01


Background: Breast cancer is a heterogeneous disease that represents a major public health problem. The immunohistochemical determination of breast cancer subtypes with regard to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) status can contribute to improved selection of therapy and patientcare. The purpose of this study was to determine the prevalence of the molecular breast cancer subtypes and to assess their associations with classical clinicopathologic parameters for better therapeutic decisions in women with breast cancer in the Ivory Coast. Materials and Methods: Formalin-fixed and paraffin-embedded blocks of patients diagnosed with primary breast carcinoma were subjected to immunohistochemical assay for the assessment of ER/RP and HER2 expression. The one-way analysis of variance evaluated the difference between breast cancer subtypes and mean age of patients. The Chi-square Test was used to compare standard clinicopathologic prognostic parameters with tumor subtypes. Results. Among 302 patients, 57% were premenopausal and 43% were postmenopausal. The invasive ductal carcinoma not otherwise specified (IDC NOS) (82.8%) was the most frequent histological type, and the tumor grade 2 (56%) was predominant followed by grade 3 (20.9%). The proportion of positivity of ER, PR, and HER2 was 56%, 49%, and 15.6%, respectively. Half of patients of this study (51.6%) had luminal A breast tumor type followed by TN (32.1%). Other subtypes were luminal B (10.1% ) and non-luminal HER2+ (6.3%). Conclusions. The findings of the present study are in line with the literature and should assist in management of breast cancer in our country.


  1. Adebamowo CA, Famooto A, Ogundiran TO, et al (2008). Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat, 110, 183-8 .
  2. Ambrosone CB, Zirpoli G, Ruszczyk M, et al (2014). Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study. Cancer Causes Control, 25, 259-65.
  3. Byar DP, Sears ME, McGuire WL (1979). Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer, 15, 299-310.
  4. Blows FM, Driver KE, Schmidt MK, et al (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med, 7, 1000279.
  5. Bauer K, Parise C, Caggiano V (2010). Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer, 10, 228.
  6. Beltjens F, Bertaut A, Pigeonnat S, et al (2015). HER2- positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable. Eur J Cancer Care, DETAILS?
  7. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA, 295, 2492-502.
  8. Coulibaly JD, Effi AB, Horo GA, et al (2008). Hormonal status and overexpression of HER2 in breast cancer, Cancerology department of Treichville UHC. Preliminary results. Bull Cancer, 95, 799-803.
  9. Elston CW, Ellis IO (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathol, 19, 403-10.
  10. Fouad A, Yousra A, Kaoutar Z, et al (2012). Molecular Classification of breast cancer in Morocco. Pan Afr Med J, 13, 9.
  11. Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: Assessed 25 Oct 2015.
  12. Gullick WJ, Srinivasan R (1998). The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat, 52, 43-53.
  13. Geyer FC, Lopez-Garcia MA, Lambros MB, Reis-Filho JS (2009). Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med, 13, 4090-103.
  14. Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A (2014). Molecular breast cancer subtypes prevalence in an indigenous Sub-Saharan African population. Pan Afr Med J, 17, 249.
  15. Huo D, Ikpatt F, Khramtsov A, et al (2009). Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. J Clin Oncol, 27, 4515-2.
  16. Hammond ME, Hayes DF, Dowsett M, et al (2010). American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med, 134, 907-22.
  17. Knight WA 3rd, Osborne CK, McGuire WL (1980). Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab, 9, 361-8.
  18. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139, 539-52.
  19. Joensuu K, Leidenius M, Kero M, et al (2013). ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancerreduced CK5 expression in metastases. Breast Cancer, 7, 23-34.
  20. Kurian AW, Fish K, Shema SJ, Clarke CA (2010). Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res, 12, 99.
  21. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al (2002). The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol, 20, 2310-2318.
  22. Lowery AJ, Miller N, Devaney A, et al (2009). MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res, 11, 27.
  23. Lin CH, Liau JY, Lu YS, et al (2009). Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev, 18, 1807-14.
  24. Ly M, Antoine M, Dembélé AK, et al (2012). High incidence of triple-negative tumors in Sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncol 83, 257-63.
  25. Kwan ML, Kushi LH, Weltzien E, et al (2009). Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res, 11, 31.
  26. Malone KE, Daling JR, Doody DR, et al (2006). Prevalence and predictors of BRCA1 and BRCA2 mutations in a population based study of breast cancer in White and Black American women ages 35 to 64 years. Cancer Res, 66, 8297-308.
  27. Millikan RC, Newman B, Tse C-K, et al (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109, 123-39.
  28. Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.
  29. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res, 7, 4-13.
  30. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
  31. Pusztai L, Ayers M, Stec J, et al (2003). Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res, 9, 2406-15.
  32. Parise CA, Bauer KR, Brown MM, Caggiano V (2009). Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J, 15, 593-602.
  33. Phipps AI, Chlebowski RT, Prentice R, et al (2011). Reproductive history and oral contraceptive use in relation to risk of triplenegative breast cancer. J Natl Cancer Inst, 103, 470-7.
  34. Parise CA, Caggiano V (2014). Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol.
  35. Pal T, Bonner D, Cragun D, et al (2015). A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer, 121, 4173-80.
  36. Ronnov-Jessen L, Petersen OW, Bissell MJ (1996). Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev, 76, 69-125.
  37. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
  38. Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100, 8418-23.
  39. Stark A, Kleer CG, Martin I, et al (2010). African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer, 16, 4926-32.
  40. Stewart WB, Wild PC (2014). World cancer report. 3rd ed. Lyon: IARC.
  41. Seshie B, Adu-Aryee NA, Dedey F, et al (2015). A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol, 15, 14.
  42. Trivers KF, Lund MJ, Porter PL, et al (2009). The epidemiology of triple-negative breast cancer, including race. CCC, 20, 1071-82.
  43. Tesfamariam A, Roy I (2013). Molecular biology of breast cancer in the horn of africa: case series-a pilot study of breast cancer from eritrea. ISRN Pathol.
  44. Werner M, Chott A, Fabiano A, Battifora H (2000). Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol, 24, 1016-9.
  45. Weigelt B, Horlings HM, Kreike B, et al (2008). Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol, 216, 141-50.
  46. Weigel MT, Dowsett M (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer, 17, 245-62.
  47. Wolff AC, Hammond ME, Hicks DG, et al (2013). American society of clinical oncology/college of american pathologists. recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol, 31, 3997-4013.